Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362585 | 0.96 | MRGPRX4 (0.35) | MRGPRX4CASRCYP1A2PARP1NR1D1 | |
| SCHEMBL15865612 | 0.93 | CYP1A2 (0.36) | MRGPRX4CYP1A2PARP1BRD4AKT1 | |
| SCHEMBL15865629 | 0.85 | MRGPRX4 (0.39) | MRGPRX4CASRCYP1A2PARP1NR1D1 | |
| SCHEMBL15865618 | 0.84 | CYP1A2 (0.36) | MRGPRX4CYP1A2PDE5ABRD4AKT1 | |
| SCHEMBL23567539 | 0.83 | NR1D1 (0.40) | MRGPRX4CASRCYP1A2NR1D1BRD4 | |
| SCHEMBL26027560 | 0.78 | MRGPRX4 (0.34) | MRGPRX4CASRCYP1A2PARP1NR1D1 | |
| SCHEMBL24722606 | 0.77 | MRGPRX4 (0.37) | MRGPRX4CASRCYP1A2PARP1NR1D1 | |
| SCHEMBL15865619 | 0.76 | KDM4E (0.46) | MRGPRX4BRD4 | |
| SCHEMBL24588392 | 0.75 | MRGPRX4 (0.32) | MRGPRX4PARP1BRD4ADORA2A | |
| SCHEMBL30801055 | 0.75 | MRGPRX4 (0.37) | MRGPRX4CYP1A2PDE5ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | FCGRT, C1QBP, H1-2 | MRGPRX4 983/4885CASR 1432/4885CYP1A2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.